TrialCell reports. Medicine2022

Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy.

Jonathan D Herman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.